US FDA AdComm For Vertex’s Sickle Cell Gene Therapy ‘Not A Concern’
The US biotech revealed the US Food and Drug Administration would be holding an advisory committee meeting for exa-cel during its second quarter earnings, but analysts are unfazed by the news amid robust revenues and raised guidance.
